Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

Articles

Key Considerations for Patients with Multiple Myeloma During the Treatment Journey

January 10th 2023

Jenny Ahlstrom, a patient with multiple myeloma, shares considerations for patients going through treatment, including toxicities, follow-up, and travel planning.

Available Induction Treatment Regimens for Patients with Transplant-Ineligible MM

January 10th 2023

Shaji Kumar, MD, and Krina Patel, MD, discuss the treatment options for patients with newly-diagnosed multiple myeloma who are not eligible for stem cell transplant.

Optimal Treatment Selection for Patients with NDMM: Updates from IMS 2022

January 3rd 2023

Dr Krina Patel discusses updates in the treatment of newly-diagnosed from recent meetings how the appropriate treatments are selected in patients with newly-diagnosed multiple myeloma.

The Role of Stem Cell Transplant in the NDMM Treatment Landscape

January 3rd 2023

Dr Shaji Kumar reviews clinical trial data on the role of stem cell transplant as a treatment for newly-diagnosed multiple myeloma in tandem with a multi-agent combination therapy.

Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

December 22nd 2022

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

December 22nd 2022

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

Induction Regimen Options for Patients with Transplant-Eligible Newly-Diagnosed Multiple Myeloma (NDMM)

December 19th 2022

Krina Patel, MD, details the three- and four-drug regimen first-line treatment options for transplant-eligible newly-diagnosed multiple myeloma and how to make an appropriate treatment decision.

Introduction to Multiple Myeloma and Resources for Patient Education after Diagnosis

December 19th 2022

Shaji Kumar, MD, provides an overview of multiple myeloma, and Jenny Ahlstrom, a patient with multiple myeloma, shares the story of her diagnosis and the resources she used to educate herself.

Improving Care in Multiple Myeloma: Unmet Needs and Future Directions

August 25th 2022

Closing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.

Use of CAR T-Cell Therapy in Earlier Lines in Multiple Myeloma

August 25th 2022

Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.

CAR T-Cell Therapy in RRMM: Adverse Event Management

August 18th 2022

Expert perspectives on how to manage adverse events associated with CAR T-Cell therapy in patients with relapsed/refractory multiple myeloma.

CAR T-Cell Therapy: KarMMa Study and the Role of Ide-Cel in RRMM

August 18th 2022

Shared insight on clinical trial data behind the KarMMa trial of ide-cel, a CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

CAR T-Cell Therapy: CARTITUDE-1 Study and the Role of Cilta-Cel in RRMM

August 11th 2022

Shifting their focus to CAR T-cell therapies, expert hematologist-oncologists review data from the CARTITUDE-1 trial of cilta-cel and its subgroup analyses.

Selection and Sequencing Of Bispecific Antibodies in RRMM and Key Takeaways

August 11th 2022

Focusing on recent clinical trial data, expert panelists take a broad look at how they might select and sequence bispecific antibody therapies in practice.

Addressing Adverse Events With Bispecific Antibodies with Focus on CRS Management

August 4th 2022

Shared insight on the adverse event profiles of novel bispecific antibody therapies, with specific focus on how CRS can be adequately managed by the health care team.

Talquetamab, Cevostamab and Elranatamab in RRMM

August 4th 2022

After reviewing other novel bispecific antibodies including talquetamab, cevostamab, and elranatamab in RRMM, panelists consider how these agents compare and might be selected for specific patients.

Teclistamab in RRMM: Patient Selection and Combining Therapies

July 28th 2022

Shifting toward the practical use of bispecific antibody teclistamab in RRMM, experts consider appropriate patient selection and investigational combination strategies.

BCMA-Targeting Bispecifics in RRMM: MajesTEC-1 Trial and Real-World Data for Teclistamab

July 28th 2022

Focusing on relapsed/refractory MM, expert panelists review data from MajesTEC-1 and consider how bispecific antibodies are impacting the treatment paradigm.

RRMM: Treatment Options in Early Relapse and in Triple-Class Refractory MM

July 21st 2022

Ajai Chari, MD provides an overview of treatment options in patients with multiple myeloma at first relapse and those with triple-refractory disease

Selecting Optimal Therapy in Transplant-Ineligible NDMM and Key Takeaways

July 21st 2022

Expert hematologist-oncologists home in on clinical trial data to consider which regimens are most appropriate for patients with transplant-ineligible NDMM.